CLINICAL STUDY
Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure
Hani N. Sabbah, PhD, FACCa,
Victor G. Sharov, MD, PhDa,
Ramesh C. Gupta, PhDa,
Anastassia Todor, MDa,
Vinita Singh, PhDa and
Sidney Goldstein, MD, FACCa
a Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan, USA
Manuscript received December 13, 1999;
revised manuscript received April 19, 2000,
accepted June 19, 2000.
Reprint requests and correspondence: Dr. Hani N. Sabbah, Cardiovascular Research, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202 HSABBAH1{at}hfhs.org
OBJECTIVES
The purpose of this study was to determine if therapy with beta-blockade is associated with reduced cardiomyocyte apoptosis.
BACKGROUND
Chronic treatment with beta-adrenergic blocking agents has been shown to improve left ventricular (LV) ejection fraction and attenuate progressive LV remodeling in heart failure (HF). Cardiomyocyte apoptosis has also been shown to occur in the failing heart.
METHODS
Moderate HF was produced in 14 dogs by intracoronary microembolizations. Dogs were randomized to three months therapy with metoprolol (MET, 25 mg twice daily, n = 7) or to no therapy at all (n = 7). At the end of three months, dogs were sacrificed, and nuclear DNA fragmentation (nDNAf), a marker of apoptosis, was assessed in LV tissue using the TUNEL assay. The number of cardiomyocytes with positive nDNAf labeling per 1,000 was quantified in LV regions bordering old infarcts and in regions remote from infarcts. Endonuclease activity and expression of the antiapoptotic protein Bcl-2 and the proapoptotic proteins Bax and caspase-3 were also evaluated in LV tissue.
RESULTS
The number of nDNAf events per 1,000 cardiomyocytes was lower in dogs treated with MET compared with untreated dogs with HF in the border regions (0.35 ± 0.07 vs. 5.32 ± 0.77, p < 0.001) as well as the remote regions (0.07 ± 0.05 vs. 0.39 ± 0.12, p < 0.05). Endonuclease activity was also significantly lower in MET-treated compared with untreated dogs (25 ± 3 vs. 37 ± 2 ng [3H]DNA rendered soluble/min/mg protein). Western blotting for Bcl-2, Bax and caspase-3 showed increased expression of Bcl-2, decreased expression of caspase-3 and no change in Bax in MET-treated compared with untreated dogs.
CONCLUSIONS
Chronic therapy with MET attenuates cardiomyocyte apoptosis in dogs with moderate HF. Attenuation of ongoing cardiomyocyte loss through apoptosis may be one mechanism through which beta-blockers elicit their benefits in HF.
|
Abbreviations and Acronyms
| | CSQ | = calsequestrin | | HF | = heart failure | | LV | = left ventricular | | MET | = metoprolol | | nDNAf | = nuclear DNA fragmentation | | SDS | = sodium dodecyl sulfate | | TdT | = terminal deoxynucleotidal transferase | | TUNEL | = TdT-mediated dUTP nick-end labeling |
|
This article has been cited by other articles:

|
 |

|
 |
 
M. Park, Y.-T. Shen, V. Gaussin, G. R. Heyndrickx, J. Bartunek, R. R. G. Resuello, F. F. Natividad, R. N. Kitsis, D. E. Vatner, and S. F. Vatner
Apoptosis predominates in nonmyocytes in heart failure
Am J Physiol Heart Circ Physiol,
August 1, 2009;
297(2):
H785 - H791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Sampat, P. Varadarajan, R. Turk, A. Kamath, S. Khandhar, and R. G. Pai
Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients.
J. Am. Coll. Cardiol.,
July 28, 2009;
54(5):
452 - 457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Groban and J. Butterworth
Perioperative management of chronic heart failure.
Anesth. Analg.,
September 1, 2006;
103(3):
557 - 575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. C. Okere, M. P. Chandler, T. A. McElfresh, J. H. Rennison, V. Sharov, H. N. Sabbah, K.-Y. Tserng, B. D. Hoit, P. Ernsberger, M. E. Young, et al.
Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin
Am J Physiol Heart Circ Physiol,
July 1, 2006;
291(1):
H38 - H44.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. P.M. van Empel, A. T.A. Bertrand, L. Hofstra, H. J. Crijns, P. A. Doevendans, and L. J. De Windt
Myocyte apoptosis in heart failure
Cardiovasc Res,
July 1, 2005;
67(1):
21 - 29.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Syed, H. S. Hahn, A. Odley, Y. Guo, J. G. Vallejo, R. A. Lynch, D. L. Mann, R. Bolli, and G. W. Dorn II
Proapoptotic Effects of Caspase-1/Interleukin-Converting Enzyme Dominate in Myocardial Ischemia
Circ. Res.,
May 27, 2005;
96(10):
1103 - 1109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Iwatsubo, S. Minamisawa, T. Tsunematsu, M. Nakagome, Y. Toya, J. E. Tomlinson, S. Umemura, R. M. Scarborough, D. E. Levy, and Y. Ishikawa
Direct Inhibition of Type 5 Adenylyl Cyclase Prevents Myocardial Apoptosis without Functional Deterioration
J. Biol. Chem.,
September 24, 2004;
279(39):
40938 - 40945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawai, F. Qin, J. Shite, W. Mao, S. Fukuoka, and C.-s. Liang
Importance of antioxidant and antiapoptotic effects of {beta}-receptor blockers in heart failure therapy
Am J Physiol Heart Circ Physiol,
September 1, 2004;
287(3):
H1003 - H1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Omerovic, E. Bollano, B. Soussi, and F. Waagstein
Selective {beta}1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure
Eur J Heart Fail,
December 1, 2003;
5(6):
725 - 732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Lohse, S. Engelhardt, and T. Eschenhagen
What Is the Role of {beta}-Adrenergic Signaling in Heart Failure?
Circ. Res.,
November 14, 2003;
93(10):
896 - 906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Eichhorn, P. A. Grayburn, S. A. Mayer, M. St John Sutton, C. Appleton, J. Plehn, J. Oh, B. Greenberg, A. DeMaria, R. Frantz, et al.
Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With {beta}-Blockade in Patients With Heart Failure: The {beta}-Blocker Evaluation of Survival Trial (BEST)
Circulation,
November 11, 2003;
108(19):
2336 - 2341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Bussani, A Abbate, G G L Biondi-Zoccai, A Dobrina, A M Leone, D Camilot, M P Di Marino, F Baldi, F Silvestri, L M Biasucci, et al.
Right ventricular dilatation after left ventricular acute myocardial infarction is predictive of extremely high peri-infarctual apoptosis at postmortem examination in humans
J. Clin. Pathol.,
September 1, 2003;
56(9):
672 - 676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. G.L. Biondi-Zoccai, A. Abbate, and A. Baldi
Potential Antiapoptotic Activity of Aldosterone Antagonists in Postinfarction Remodeling
Circulation,
July 29, 2003;
108
(4):
e26 - e26.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Q. Z.-Q. Zhao, C. D. Morris, J. M. Budde, N.-P. N.-P. Wang, S. Muraki, H.-Y. H.-Y. Sun, and R. A. Guyton
Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion
Cardiovasc Res,
July 1, 2003;
59(1):
132 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Abbate, G. G. L. Biondi-Zoccai, R. Bussani, A. Dobrina, D. Camilot, F. Feroce, R. Rossiello, F. Baldi, F. Silvestri, L. M. Biasucci, et al.
Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure
J. Am. Coll. Cardiol.,
March 5, 2003;
41(5):
753 - 760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mishra, H. N. Sabbah, J. C. Jain, and R. C. Gupta
Reduced Ca2+-calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure
Am J Physiol Heart Circ Physiol,
March 1, 2003;
284(3):
H876 - H883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Pearl, D. P. Nelson, S. M. Schwartz, C. J. Wagner, S. M. Bauer, E. A. Setser, and J. Y. Duffy
Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts
Ann. Thorac. Surg.,
September 1, 2002;
74(3):
830 - 837.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thielmann, H. Dorge, C. Martin, S. Belosjorow, U. Schwanke, A. van de Sand, I. Konietzka, A. Buchert, A. Kruger, R. Schulz, et al.
Myocardial Dysfunction With Coronary Microembolization: Signal Transduction Through a Sequence of Nitric Oxide, Tumor Necrosis Factor-{alpha}, and Sphingosine
Circ. Res.,
April 19, 2002;
90(7):
807 - 813.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Goldstein
Benefits of {beta}-Blocker Therapy for Heart Failure: Weighing the Evidence
Arch Intern Med,
March 25, 2002;
162(6):
641 - 648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Condorelli, R. Roncarati, J. Ross Jr., A. Pisani, G. Stassi, M. Todaro, S. Trocha, A. Drusco, Y. Gu, M. A. Russo, et al.
Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function
PNAS,
August 14, 2001;
98(17):
9977 - 9982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thielmann, H. Dorge, C. Martin, S. Belosjorow, U. Schwanke, A. van de Sand, I. Konietzka, A. Buchert, A. Kruger, R. Schulz, et al.
Myocardial Dysfunction With Coronary Microembolization: Signal Transduction Through a Sequence of Nitric Oxide, Tumor Necrosis Factor-{alpha}, and Sphingosine
Circ. Res.,
April 19, 2002;
90(7):
807 - 813.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|